MedTrace Logo

A Study Evaluating HBM9036 Efficacy and Safety on Moderate to Severe Dry Eye

NCT04633213 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 577

Last updated 2026-04-28

No results posted yet for this study

Summary

The objective of this study is to compare the safety and efficacy of 0.25% HBM9036 (HL036) Ophthalmic Solution to placebo for the treatment of the Chinese subjects with moderate and severe dry eye.

Conditions

  • Dry Eye

Interventions

DRUG

HBM9036 0.25% Ophthalmic Solution

Ophthalmic Solution

DRUG

Placebo

Ophthalmic Solution

Sponsors & Collaborators

  • Harbour BioMed (Guangzhou) Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Zuguo Liu, Doctor · Xiamen Eye Center Affiliated to Xiamen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-25
Primary Completion
2022-08-07
Completion
2022-08-07

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04633213 on ClinicalTrials.gov